Comparison of Abbott ID Now and Abbott m2000 Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients
Amanda Harrington, Brian Cox, Jennifer Snowdon, Jonathan Bakst, Erin Ley, Patricia Grajales, Jack A. Maggiore, Stephen E. Kahn
Abstract
The ID Now COVID-19 (IDNCOV) assay performed on the ID Now instrument (Abbott Diagnostics, Inc., Scarborough, ME) is a rapid diagnostic test that can be performed in a point-of-care setting equivalent to Clinical Laboratory Improvement Amendments (CLIA)-waived testing. The assay utilizes isothermal amplification and can reportedly deliver results in approximately 5 to 13 min. As this assay could provide significant improvements to workflow in our hospital system, we sought to compare the performance of this test with our current coronavirus disease 2019 (COVID-19) assay, the Abbott RealTime SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) (ACOV) assay performed on the Abbott m2000 system (Abbott Molecular Inc., Des Plaines, IL).